Stigma and Substance Use as Barriers to PrEP Linkage, Uptake, Adherence, and Persistence among BMSM

污名和物质使用是 BMSM 之间 PrEP 联系、吸收、坚持和持久性的障碍

• 批准号: 10402891
• 负责人: Lisa A Eaton
• 金额: $ 62.21万
• 依托单位: UNIVERSITY OF CONNECTICUT STORRS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-15 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10402891
• 关键词: AIDS prevention; AIDS/HIV problem; Address; Adherence; Affect; Awareness; Behavior; Behavioral; Biological; Biological Markers; Blood; COVID-19; COVID-19 impact; Caring; Centers for Disease Control and Prevention (U.S.); Cocaine; Connecticut; Continuity of Patient Care; Counseling; Data; Drug abuse; Eligibility Determination; Enrollment; Ethnic Origin; Failure; Follow-Up Studies; Guidelines; HIV; HIV Infections; HIV Seronegativity; HIV Seropositivity; HIV risk; HIV/STD; Healthcare; Heroin; Human immunodeficiency virus test; Incidence; Individual; Infrastructure; Inhalant dose form; Intervention; Left; Longitudinal Studies; Measures; Mediating; Modeling; Nitrates; Opioid; Outcome; Participant; Pathway interactions; Population; Positioning Attribute; Prevalence; Prevention approach; Procedures; Process; Prospective cohort; Psychosocial Assessment and Care; Public Health; Race; Reporting; Research; Risk; Role; Sex Behavior; Site; Southeastern United States; Spottings; Testing; Toxicology; Translating; Treatment Efficacy; United States National Institutes of Health; Universities; Vulnerable Populations; Work; base; black men who have sex with men; ecstasy; efficacy testing; evidence base; health care availability; improved; insight; interest; intersectionality; marijuana use; men who have sex with men; novel; pre-exposure prophylaxis; prevent; racial disparity; recruit; response; sexually active; social stigma; social structure; substance use; substance user; transmission process; uptake

This application is in response to PAS-18-915 HIV/AIDS High Priority Drug Abuse Research. HIV incidence among Black men who have sex with men (BMSM) in the southeastern United States is one of the highest in the world. Our research team has conducted studies with BMSM in Atlanta that have demonstrated 35% HIV prevalence and over 5% annual HIV incidence. Although PrEP is highly effective for preventing HIV transmission, it is not reaching BMSM. The failures in our ability to engage BMSM in PrEP use are highly problematic given the alarming rates of HIV transmission among this group. In our most recent work with BMSM in Atlanta, we found that only 4% (n=19/474) of BMSM are currently taking PrEP even though 90% (n=428/474) are aware of PrEP. Of particular concern is the impact of substance use as a barrier in PrEP linkage, uptake, adherence, and persistence. Substance use is common among BMSM in our study, with 43% (n=204/474) reporting recent substance use. And, critically, in our most recent longitudinal study with BMSM, substance users were more than twice as likely than non-substance users to test HIV positive, 7% (n=15/205) vs. 2% (n=4/244) at baseline testing, and an additional 7% (n=13/190) vs 3% (n=8/240) at study follow up one year later. Further complicating PrEP use is the potential impact of COVID- 19 on health care access, health care infrastructure, and sex behavior. The need to better understand PrEP use in the context of our new health care landscape is critical to making advances in PrEP use. At this point, assessing how substance use impacts PrEP use is challenging because PrEP implementation is so low among this group. The proposed research aims to provide substance using BMSM with evidence-based PrEP engagement counseling to address barriers to accessing PrEP (not for intervention testing, but for facilitating PrEP use) and to assess the multiple forms and paths of stigma and substance use as they relate to PrEP linkage, uptake, adherence, and persistence. We propose using the HIV Stigma Framework as a conceptual model for investigating the intersecting pathways of stigma drivers and stigma mechanisms as they relate to PrEP use among substance using BMSM. Aim 1: Enroll a prospective cohort of N=500 BMSM who test HIV negative and test substance use positive on toxicology testing, and provide evidence-based PrEP engagement counseling to facilitate access to PrEP care. Aim 2: Conduct psychosocial and health care access assessments every 2-months for 18-months, and conduct HIV/STI testing and dried blood spot testing for TFV-DP every 3-months for 18-months. Aim 3: Using data collected from Aims 1 and 2, model stigma pathways of advancing and reverting along the PrEP cascade (i.e., linkage, uptake, adherence, persistence), with these pathways mediated by health care access and moderated by substance use. Achieving the aims will provide critical insight for translating and adapting interventions to enhance potency and durability for individuals at exceedingly elevated risk for HIV.

此申请是为了响应PAS-18-915艾滋病毒/艾滋病高优先药物滥用研究。艾滋病毒感染率